In the “2018 APLAR axial spondyloarthritis treatment recommendations” study, a working group representing 15 countries from the Asia-Pacific region provides fourteen up-to-date recommendations for the treatment of axial spondyloarthritis, a chronic inflammatory disease that predominantly affects the spine or sacroiliac joints. Given the wide variations in predisposition to infections and other patient factors, local practice patterns, and access to treatment across countries, the region-specific guideline adds substantial value for clinicians to help meet the needs of patients (Int J Rheum Dis. 2019 Mar;22(3):340-356. doi: 10.1111/1756-185X.13510. Epub 2019 Feb 28).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator, Prof Lai-Shan Tam of our Department of Medicines and Therapeutics. Prof Tam is head of the Division of Rheumatology and her current research focuses on inflammation and glucocorticoid induced bone loss in patients with rheumatic diseases.